Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to report that their new R&D building is on schedule to be completed later this year.
This expansion at Flamma’s headquarters that will allow Flamma to quadruple its R&D space and allow for the addition of 50 employees to join the R&D and analytical teams. This will also allow for the currently shared space that hosts both analytical and R&D groups to become solely the analytical building. This will free up more space for additional analytical equipment to augment Flamma’s capabilities.
Meanwhile, Flamma USA has recently commissioned several GMP laboratories at its Malvern, PA site. The pilot plant is GMP and numerous kilo labs are also GMP. The Flamma USA site offers an attractive alternative to the other GMP facilities in North America and also allows an easy entrance into the Flamma Group’s other sites in Italy and China.
